FY2024 EPS Forecast for Cocrystal Pharma Boosted by Analyst

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Investment analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Cocrystal Pharma in a report released on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($1.87) for the year, up from their previous estimate of ($2.03). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.50) EPS.

Cocrystal Pharma Price Performance

Cocrystal Pharma stock opened at $2.06 on Friday. The business has a 50 day simple moving average of $2.16 and a 200-day simple moving average of $1.99. The stock has a market capitalization of $20.95 million, a PE ratio of -1.11 and a beta of 1.53. Cocrystal Pharma has a 12 month low of $1.33 and a 12 month high of $3.26.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.